2-methyl-8-nitro-1,2,3,4-tetrahydro-7-isoquinolinamine

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 喹啉及其衍生物
• 英文名称: 2-methyl-8-nitro-1,2,3,4-tetrahydro-7-isoquinolinamine
• 英文别名: 2-methyl-8-nitro-3,4-dihydro-1H-isoquinolin-7-amine
• 化学式: C₁₀H₁₃N₃O₂
• 分子量: 207.232
• InChiKey: GGZBCCQHZIJVEU-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.5
• 重原子数：
  15
• 可旋转键数：
  0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.4
• 拓扑面积：
  75.1
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  2-methyl-8-nitro-1,2,3,4-tetrahydro-7-isoquinolinamine 在 四(三苯基膦)钯 双氧水 、 三氟乙酸 、 三氟乙酸酐 、 sodium nitrite 作用下， 以 乙二醇二甲醚 、 二氯甲烷 、 水 为溶剂， 反应 34.17h， 生成 3-ethyl-9-methyl-7,8,9,10-tetrahydro[1,2,4]triazino[5,6-h]isoquinoline 1,4-dioxide
  参考文献：
  名称：

  WO2006/104406

  摘要：

  公开号：
• 作为产物：
  描述：

  N-(2-methyl-1,2,3,4-tetrahydro-7-isoquinolinyl)acetamide 在 硫酸 、 potassium nitrate 、 盐酸 作用下， 以 水 为溶剂， 反应 4.5h， 以30%的产率得到2-methyl-8-nitro-1,2,3,4-tetrahydro-7-isoquinolinamine
  参考文献：
  名称：

  Tricyclic [1,2,4]Triazine 1,4-Dioxides As Hypoxia Selective Cytotoxins

  摘要：

  A series of novel tricyclic triazine-di-N-oxides (TTOs) related to tirapazamine have been designed and prepared. A wide range of structural arrangements with cycloalkyl, oxygen-, and nitrogen-containing Saturated rings fused to the triazine core, coupled with various side chains linked to either hemisphere, resulted in TTO analogues that displayed hypoxia-selective cytotoxicity in vitro. Optimal rates of hypoxic metabolism and tissue diffusion coefficients were achieved with fused cycloalkyl rings in combination with both the 3-aminoalkyl or 3-alkyl substituents linked to weakly basic soluble amines. The selection was further refined 7 using pharmacokinetic/phamacodynamic model predictions of the in vivo hypoxic potency (AUC(req)) and selectivity (HCD) with 12 TTO analogues predicted to be active in Vivo, Subject to the achievement of adequate plasma pharmacokinetics.

  DOI：

  10.1021/jm800967h

文献信息

• Tricyclic 1,2,4-triazine oxides and compositions for therapeutic use in cancer treatments
  申请人：Auckland Uniservices Limited

  公开号：US07989451B2

  公开（公告）日：2011-08-02

  The invention relates to novel tricyclic 1,2,4-triazine-1-oxides and novel tricyclic 1,2,4-triazine-1,4-dioxides of formula I and to related analogues, to their preparation, and to their use as hypoxia-selective drugs and radiosensitizers for cancer therapy, both alone or in combination with radiation and/or other anticancer drugs.

  本发明涉及新型三环1,2,4-三嗪-1-氧化物和新型三环1,2,4-三嗪-1,4-二氧化物的公式I以及相关类似物，涉及它们的制备，以及它们作为缺氧选择性药物和放射增敏剂用于癌症治疗，无论是单独使用还是与放射治疗和/或其他抗癌药物联合使用。
• Tricyclic 1,2,4-Triazine Oxides and Compositions for Therapeutic Use in Cancer Treatments
  申请人：Hay Michael Patrick

  公开号：US20090186886A1

  公开（公告）日：2009-07-23

  The invention relates to novel tricyclic 1,2,4-triazine-1-oxides and novel tricyclic 1,2,4-triazine-1,4-dioxides of formula I and to related analogues, to their preparation, and to their use as hypoxia-selective drugs and radiosensitizers for cancer therapy, both alone or in combination with radiation and/or other anticancer drugs.

  本发明涉及新型三环1,2,4-三嗪-1-氧化物和新型三环1,2,4-三嗪-1,4-二氧化物的公式I以及相关类似物，它们的制备以及它们作为低氧选择性药物和放射增敏剂用于癌症治疗，可以单独使用或与放射线和/或其他抗癌药物联合使用。
• TRICYCLIC 1,2,4-TRIAZINE OXIDES AND COMPOSITIONS THEREFROM FOR THERAPEUTIC USE IN CANCER TREATMENTS
  申请人：AUCKLAND UNISERVICES LIMITED

  公开号：EP1866292B1

  公开（公告）日：2010-12-15
• US7989451B2
  申请人：——

  公开号：US7989451B2

  公开（公告）日：2011-08-02
• [EN] TRICYCLIC 1,2,4-TRIAZINE OXIDES AND COMPOSITIONS THEREFROM FOR THERAPEUTIC USE IN CANCER TREATMENTS<br/>[FR] OXYDES DE 1,2,4-TRIAZINE TRICYCLIQUES ET LEURS COMPOSITIONS A USAGE THERAPEUTIQUE DANS LES TRAITEMENTS ANTICANCEREUX
  申请人：AUCKLAND UNISERVICES LTD

  公开号：WO2006104406A1

  公开（公告）日：2006-10-05

  [EN] The invention relates to novel tricyclic 1,2,4-triazine-1-oxides and novel tricyclic 1,2,4-triazine-1,4-dioxides of formula: (I); and to related analogues, to their preparation, and to their use as hypoxia-selective drugs and radiosensitizers for cancer therapy, both alone or in combination with radiation and/or other anticancer drugs.
  [FR] La présente invention se rapporte à des 1-oxydes de 1,2,4-triazine tricycliques innovants et à des 1,4-dioxydes de 1,2,4-triazine tricycliques innovants de formule : (I), ainsi qu'aux analogues apparentés. Elle se rapporte également à leur préparation et à leur utilisation en tant que médicaments sélectifs de l'hypoxie et que radiosensibilisants destinés au traitement du cancer, seuls ou en combinaison avec une radiothérapie et/ou d'autres médicaments anticancéreux.